Bora Group expands US biologics footprint with US$127.5M MacroGenics CDMO acquisition

USA—Taiwan-based Bora Pharmaceuticals has agreed to acquire the contract development and manufacturing organization (CDMO) business and manufacturing operations of MacroGenics in a deal valued at up to US$127.5 million.

Under the agreement, Bora will pay US$122.5 million upfront, with an additional US$5 million contingent on future customer orders and other conditions tied to the transaction.

The acquisition includes MacroGenics’ biologics drug substance manufacturing facility in Rockville, Maryland, as well as a warehousing center in Frederick, Maryland, located about 30 miles away.

Bora strengthens biologics manufacturing capacity

The acquisition significantly expands Bora’s biologics manufacturing capabilities in the United States as the company accelerates its push into the global CDMO market.

Bora said the Rockville site currently generates more than half of its revenue from commercial manufacturing activities, highlighting the facility’s established customer base and operational maturity.

The Maryland facility includes five 2,000-liter and two 500-liter single-use bioreactors, alongside integrated quality control and analytical laboratories.

The site has also undergone inspections by both the U.S. Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

Bobby Sheng, chairperson and CEO of Bora Group, described the acquisition as a major milestone in expanding the company’s integrated biologics platform in North America.

He said the addition of the Rockville facility would increase Bora Biologics’ total drug substance manufacturing capacity to 20,000 liters.

He also noted that Bora plans to integrate its in-house drug substance and drug product operations over the next 12 to 18 months to create a seamless development-to-commercialisation service for biotechnology customers.

Following completion of the transaction, Bora and Tanvex Biopharma, which operates Bora’s biologics CDMO franchise under the Bora Biologics brand, will jointly use the Rockville site to scale the group’s end-to-end biologics manufacturing platform.

MacroGenics sharpens focus on oncology pipeline

For MacroGenics, the divestiture forms part of a broader strategy to streamline operations and concentrate resources on oncology drug development.

The company recently stated that the transaction would provide substantial non-dilutive funding to support key pipeline milestones expected in 2026 and beyond.

MacroGenics President and CEO Eric Risser said the deal aligns with the company’s goal of becoming a more focused organization centered on innovative antibody-based cancer therapies.

He added that the company would continue working with Bora through a long-term supply and CDMO services agreement after the transaction closes.

Approximately 140 MacroGenics employees are expected to transition to Bora once the deal is finalized, which is anticipated in the third quarter of 2026, subject to customary closing conditions.

Bora expands global manufacturing partnerships

The acquisition comes only months after Bora renewed a US$250 million manufacturing partnership with British pharmaceutical company GSK.

The five-year agreement covers end-to-end manufacturing services for more than 20 commercial product lines and over 335 individual products addressing conditions such as HIV, malaria, pneumonia, migraine, eczema, psoriasis, depression, and parasitic infections.

Bora has continued expanding its international CDMO presence through acquisitions and infrastructure investments across Taiwan, Canada, and the United States, as demand for outsourced biologics manufacturing services rises.